Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation

Journal of Immunology

Volumn 170, Issue 11, 2003, Pages 5615-5624

  Dolganiuc, Angela ^a   Kodys, Karen ^a   Kopasz, Andrea ^a   Marshall, Christopher ^a   Do, Twan ^a   Romics Jr , Laszlo ^a   Mandrekar, Pranoti ^a   Zapp, Maria ^a   Szabo, Gyongyi ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; CYTOKINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; MESSENGER RNA; NONSTRUCTURAL PROTEIN 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ADULT; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL STIMULATION; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; T LYMPHOCYTE;

EID: 0037851770     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.11.5615     Document Type: Article

References (65)

1. Boyer, N., and P. Marcellin. 2000. Pathogenesis, diagnosis and management of hepatitis C. Hepatology 32:98.
2. El-Serag, H. B. 2002. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36:S74.
3. + T cells in chronic hepatitis C virus infection. J. Immunol. 169:3447.
4. Jackson, M., B. Smith, D. J. Bevitt, M. Steward, G. L. Toms, M. F. Bassendine, and A. G. Diamond. 1999. Comparison of cytotoxic T-lymphocyte responses to hepatitis C virus core protein in uninfected and infected individuals. J. Med. Virol. 58:239.
5. Maldonado-López, R., and M. Moser. 2001. Dendritic cell subsets and the regulation of Th1/Th2 responses. Immunology 13:275.
6. Langenkamp, A., M. Messi, A. Lanzavecchia, and F. Sallusto. 2000. Kinetics of dendritic cell activation: impact on priming of Th1, Th2 and nonpolarized T cells. Nat. Immun. 1:311.
7. Kanto, T., N. Hayashi, T. Takehara, T. Tatsumi, N. Kuzushita, A. Ito, Y. Sasaki, A. Kasahara, and M. Hori. 1999. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J. Immunol. 162:5584.
8. Bain, C., A. Fatmi, F. Zoulim, J. P. Zarski, C. Trépo, and G. Inchauspé. 2001. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120:512.
9. Auffermann-Gretzinger, S., E. B. Keeffe, and S. Levy. 2001. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97:3171.
10. Lerat, H., S. Rumin, F. Habersetzer, F. Berby, M. A. Trabaud, C. Trépo, and G. Inchauspé. 1998. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood 91:3841.
11. Mellor, J., G. Haydon, C. Blair, W. Livingstone, and P. Simmonds. 1998. Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells. J. Gen. Virol. 79:705.
12. Caussin-Schwemling, C., C. Schmitt, and F. Stoll-Keller. 2001. Study of the infection of human blood derived monocytes/macrophages with hepatitis C virus in vitro. J. Med. Virol. 65:14.
13. Rosenberg, S. 2001. Recent advances in the molecular biology of hepatitis C virus. J. Mol. Biol. 313:451.
14. Kato, N. 2001. Molecular virology of hepatitis C virus. Acta Med. Okayama 55:133.
15. Bouvier-Alias, M., K. Patel, H. Dahari, S. Beaucourt, P. Larderie, L. Blatt, C. Hezode, G. Picchio, D. Dhumeaux, A. Neumann, et al. 2002. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 36:211.
16. Ray, R. B., and R. Ray. 2001. Hepatitis C virus core protein: intriguing properties and functional relevance. FEMS Microbiol. Lett. 202:149.
17. McLauchlan, J. 2000. Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J. Viral Hep. 7:2.
18. Wünschmann, S., J. D. Medh, D. Klinzmann, W. N. Schmidt, and J. T. Stapleton. 2000. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J. Virol. 74:10055.
19. Scarselli, E., H. Ansuini, R. Cerino, R. M. Roccasecca, S. Acali, G. Filocamo, C. Traboni, A. Nicosia, R. Cortese, and A. Vitelli. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21:5017.
20. Zemel, R., S. Gerechet, H. Grief, L. Bachmatove, Y. Birk, A. Golan-Goldhirsh, M. Kunin, Y. Berdichevsky, I. Behar, and R. Tur-Kaspa. 2001. Cell transformation induced by hepatitis C virus NS3 serine protease. J. Viral. Hep. 8:96.
21. Locatelli, G. A., G. Gosselin, S. Spadari, and G. Maga. 2001. Hepatitis C virus NS3 NTPase/helicase: different stereoselectivity in nucleoside triphosphate utilization suggests that NTPase and helicase activities are coupled by a nucleotidedependent rate limiting step. J. Mol. Biol. 313:683.
22. Mandrekar, P., D. Catalano, and G. Szabo. 1999. Inhibition of lipopolysaccharide-mediated NF-κB activation by ethanol in human monocytes. Int. Immunol. 11:1781.
23. Szabo, G., C. Gavala, and P. Mandrekar. 2001. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J. Invest. Med. 49:442.
24. Szabo, G., B. Verma, and D. Catalano. 1993. Selective inhibition of antigenspecific T lymphocyte proliferation by acute ethanol exposure: the role of impaired monocyte antigen presentation capacity and mediator production. J. Leukocyte Biol. 54:534.
25. Zou, W., J. Borvak, S. Wei, T. Isaeva, D. T. Curiel, and T. J. Curiel. 2001. Reciprocal regulation of plasmacytoid dendritic cells and monocytes during viral infection. Eur. J. Immunol. 31:3833.
26. Larsson, M., J. F. Fonteneau, S. Somersan, C. Sanders, K. Bickham, E. K. Thomas, K. Mahnke, and N. Bhardwaj. 2001. Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Eur. J. Immunol. 31:3432.
27. Yoshimura, S., J. Bondeson, B. M. J. Foxwell, F. M. Brennan, and M. Feldmann. 2001. Effective antigen presentation by dendritic cells is NF-κB dependent: coordinate regulation of MHC co-stimulatory molecules and cytokines. Int. Immunol. 13:675.
28. Mellman, I., and R. M. Steinman. 2001. Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255.
29. + lymphocytes in portal infiltrates in chronic hepatitis C. Histopathology 39:373.
30. Van Gool, S. W., P. Vandenberghe, M. de Boer, and J. L. Ceuppens. 1996. CD80, CD86 and CD40 provide accessory signal in a multi-step T-cell activation model. Immunol. Rev. 153:47
31. Corinti, S., C. Albanesi, A. La Sala, S. Pastore, and G. Girolomoni. 2001. Regulatory activity of autocrine IL-10 on dendritic cell functions. J. Immunol. 166:4312.
32. + T cells. J. Immunol. 162:3256.
33. Chen, M. L., F. H. Wang, P. K. Lee, and C. M. Lin. 2001. Interleukin-10-induced T cell unresponsiveness can be reversed by dendritic cell stimulation. Immunol. Lett. 75:91.
34. Granucci, F., C. Vizzardelli, E. Virzi, M. Rescigno, and P. Ricciardi-Castagnoli. 2001. Transcriptional reprogramming of dendritic cells by differentiation stimuli. Eur. J. Immunol. 31:2539.
35. McGuinness, P. H., D. Painter, S. Davies, and G. W. McCaughan. 2000. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 46:260.
36. Neuman, M. G., J. P. Benhamou, I. M. Malkiewicz, R. Akremi, N. H. Shear, T. Asselah, A. Ibrahim, N. Boyer, M. Martinot-Peignoux, P. Jacobson-Brown, et al. 2001. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin. Biochem. 34:173.
37. Amaraa, R., H. Mareckova, P. Urbanek, and T. Fucikova. 2002. Production of interleukins 10 and 12 by activated peripheral blood monocytes/macrophages in patients suffering from chronic hepatitis C virus infection with respect to the response to interferon and ribavirin treatment. Immunol. Lett. 83:209.
38. Zekry, A., G. A. Bishop, D. G. Bowen, M. M. Gleeson, S. Guney, D. M. Painter, and G. W. McCaughan. 2002. Intrahepatic cytokine profiles associated with posttransplantational hepatitis C virus-related liver injury. Liver Transpl. 8:292.
39. Li, Q., and I. M. Verma. 2002. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2:725.
40. Haeberle, H. A., R. Takizawa, A. Casola, A. R. Brasier, H. J. Dieterich, N. V. Rooijen, Z. Gatalica, and R. P. Garofalo. 2002. Respiratory syncytial virusinduced activation of nuclear factor-κB in the lung involves alveolar macrophages and Toll-like receptor 4-dependent pathways. J. Infect. Dis. 186:1199.
41. Harvard, L., P. Delvenne, P. Fraré, J. Boniver, and S. L. Giannini. 2002. Differential production of cytokines and activation of NF-κB in HPV-transformed keratinocytes. Virology 298:271.
42. Erlandsson, A. C., L. G. Bladh, P. Stierna, T. Yucel-Lindberg, O. Hammarsten, T. Modéer, J. Harmenberg, and A. C. Wikström. 2002. Herpes simplex virus type 1 infection and glucocorticoid treatment regulate viral yield, glucocorticoid receptor and NF-κB levels. J. Endocrinol. 175:165.
43. Hoffmann, A., A. Levchenko, M. L. Scott, and D. Baltimore. 2002. The IκBNF-κB signaling module: temporal control and selective gene activation. Science 298:1241.
44. Marusawa, H., M. Hijikata, T. Chiba, and K. Shimotohno. 1999. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor α-mediated apoptosis via NF-κB activation. J. Virol. 73:4713.
45. You, L. R., C. M. Chen, and Y. H. Wu Lee. 1999. Hepatitis C virus core protein enhances NF-κB signal pathway triggering by lymphotoxin-B receptor ligand and tumor necrosis factor α. J. Virol. 73:1672.
46. Ray, R. B., K. Meyer, and R. Ray. 2000. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 271:197.
47. Zhu, N., A. Khoshnan, R. Schneider, M. Matsumoto, G. Dennert, C. Ware, and M. M. C. Lai. 1998. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J. Virol. 72:3691.
48. Yang, S. H., C. G. Lee, C. W. Lee, E. J. Choi, S. K. Yoon, K. S. Ahn, and Y. C. Sung. 2002. Hepatitis C virus core inhibits the Fas-mediated p38 mitogen activated kinase signaling pathway in hepatocytes. Mol. Cell 13:452.
49. Ray, R. B., K. Meyer, A. Shrivastava, B. B. Aggarwaland, and R. Ray. 1991. Inhibition of tumor necrosis factor (TNF-α)-mediated apoptosis by hepatitis C virus core protein. J. Biol. Chem. 273:2256.
50. Yao, Z. Q., D. T. Nguyen, A. I. Hiotellis, and Y. S. Hahn. 2001. Hepatitis C virus core protein inhibits human T lymphocyte responses by a complement-dependent regulatory pathway. J. Immunol. 167:5264.
51. Denys, A., I. A. Udalova, C. Smith, L. M. Williams, C. J. Ciesielski, J. Campbell, C. Andrews, D. Kwaitkowski, and B. M. J. Foxwell. 2002. Evidence for a dual mechanism for IL-10 suppression of TNF-α production that does not involve inhibition of p38 mitogen-activated protein kinase or NF-κB in primary human macrophages. J. Immunol. 168:4837.
52. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192:1213.
53. Joss, A., M. Akdis, A. Faith, K. Blaser, and C. Akdis. 2000. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur. J. Immunol. 30:1638.
54. Buelens, C., F. Willems, A. Delvaux, G. Pierard, J. P. Delville, T. Velu, and M. Goldman. 1995. Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur. J. Immunol. 25:2668.
55. Steinbrink K., M. Wolfl, H. Jonuleit, J. Knop, and A. H. Enk. 1997. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159:4772.
56. Jonuleit, H., E. Schmitt, K. Steinbrink, and A. H. Enk. 2001. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 22:394.
57. Blankenstein, T., and T. Schuler. 2002. Cross-priming versus cross-tolerance: are two signals enough? Trends Immunol. 23:171.
58. Goldmann, O., M. Rohde, and E. Medina. 2002. Phagocytosis of bacilli Calmette-Guerin-infected necrotic macrophages induces a maturation phenotype and evokes antigen-presentation functions in dendritic cells. Immunology 107:500.
59. Horiike, N., S. A. Fazle, T. Ninomiya, M. Abe, K. Michitaka, and M. Onji. 2002. Activation and maturation of antigen-presenting dendritic cells during vaccine therapy in patients with chronic hepatitis due to hepatitis B virus. Hepatol. Res. 23:38.
60. Fanales-Belasio, E., S. Moretti, F. Nappi, G. Barillari, F. Micheletti, A. Cafaro, and B. Ensoli. 2002. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J. Immunol. 168:197.
61. Flores-Romo, L., and Z. Cinvestav-lpn. 2001. In vivo maturation and migration of dendritic cells. Immunology 102:255.
62. Andre, P., F. Komurian-Pradel, S. Deforges, M. Perret, J. L. Berland, M. Sodoyer, S. Pol, C. Brechot, G. Paranhos-Baccala, and V. Lotteau. 2002. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 76:6919.
63. Farinati, F., R. Cardin, M. Fiorentino, A. D'Errico, W. Grigioni, and A. Cecchetto. 2001. Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease. J. Viral Hep. 8:34.
64. Kimura, K., K. Kakimi, S. Wieland, L. Guidotti, and F. Chisari. 2002. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J. Immunol. 169:5188.
65. Caradonna, L., M. L. Mastronardi, T. Magrone, R. Cozzolongo, R. Cuppone, O. G. Manghisi, D. Caccavo, N. M. Pellegrino, A. Amoroso, E. Jirillo, and L. Amati. 2002. Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection. Curr. Pharm Des. 8:995.